nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.12.2009 | Symposium in Writing

Immunosenescence and cancer vaccines

verfasst von: Mauro Provinciali

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Experimental and clinical data demonstrate that ageing is associated with the gradual deterioration of the immune system, generally referred to as immunosenescence. Age-related immune dysfunction may have an impact not only on the incidence of cancer, but also on the preventive and therapeutic approaches, which are based on immune system activation. Over the last few years the use of immunological measures to prevent cancer in experimental mouse models involving preimmunisation with new vaccines against even a poor or apparently non-immunogenic tumour has yielded worse outcomes in older age than in young adults. Different mechanisms, which may be due to age-related numerical or functional dysfunction of immune cells and/or to tumour microenvironmental changes, could be responsible for this defect. This review summarises the impact of immunosenescence on the effectiveness of cancer vaccines, knowledge of cancer immunisation in old age and the potential mechanisms implicated in the poorer effectiveness of anticancer immune-based approaches in advanced age. Several approaches to, and possibilities of correcting the low effectiveness of immunisation procedures in old age are described.

Argentati K, Re F, Donnini A, Tucci MG, Franceschi C, Bartozzi B, Bernardini G, Provinciali M (2002) Numerical and functional alterations of circulating γδ T lymphocytes in aged people and centenarians. J Leukoc Biol 72:65PubMed

Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T-cells. Nat Rev Immunol 3:253PubMedCrossRef

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019PubMedCrossRef

Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR et al (2002) PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 32:634PubMedCrossRef

Casetti R, Martino A (2008) The plasticity of γδ T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 5:161PubMedCrossRef

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G (1997) Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049PubMedCrossRef

Donnini A, Argentati K, Mancini R, Smorlesi A, Bartozzi B, Bernardini G, Provinciali M (2002) Phenotype, antigen-presenting capacity, and migration of antigen-presenting cells in young and old age. Exp Gerontol 37:1097PubMedCrossRef

Donnini A, Re F, Orlando F, Provinciali M (2007) Intrinsic and microenvironmental defects are involved in the age-related changes of Lin−c-kit+ hematopoietic progenitor cells. Rejuvenation Res 10:459PubMedCrossRef

Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franceschi C, Passeri M, Sansoni P (2000) Shortage of circulating naive CD8+ T cells provides new insights on immunodeficiency in aging. Blood 95:2860PubMed

10.

Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR (2002) Human γδ T cells: a nonreduntant system in the immune-surveillance against cancer. Trends Immunol 23:14PubMedCrossRef

11.

Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Immunol 3:630CrossRef

12.

Franceschi C (2007) Inflammaging as a major characteristic of old people: can it be prevented or cured? Nutr Rev 65:S173PubMedCrossRef

13.

Francipane MG, Perez Alea M, Lombardo Y, Todaro M, Medema JP, Stassi G (2008) Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res 68:4022PubMedCrossRef

14.

Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D (2004) Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 37:684PubMedCrossRef

15.

Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA (1996) Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factorbeta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98:70PubMedCrossRef

16.

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrrello I, Zanovello P, Bicciato S, Bronte V (2006) Tumors induce a subset of inflammatory monocytes with immunosoppressive activity on CD8+ T cells. J Clin Invest 116:2777PubMedCrossRef

17.

Goodwin JS, Messner RP (1979) Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70. J Clin Invest 64:434PubMedCrossRef

18.

Gravekamp C (2007) Cancer vaccines in old age. Exp Gerontol 42:441PubMedCrossRef

19.

Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515PubMedCrossRef

20.

Gregg R, Smith CM, Clark FJ, Dunnion D, Khan N, Chakravertry R, Nayak L, Moss PA (2005) The number of human peripheral blood CD4+CD25high regulatory T cells increases with age. Clin Exp Immunol 140:540PubMedCrossRef

21.

Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, Wang J, Mountz JD, Zhang HG (2007) Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 128:672PubMedCrossRef

22.

Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737PubMedCrossRef

23.

Haugen E, Li-Ming G, Isic A, Skommevik T, Fu M (2008) Increased interleukin-6 but not tumour factor necrosis-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol 13:19PubMed

24.

Henson SM, Macaulay R, Kiani-Alikhan S, Akbar AN (2008) The use of the inhibitory receptors for modulating the immune responses. Curr Pharm Des 14:2643PubMedCrossRef

25.

Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2:1PubMed

26.

Kabelitz D, Wesch D, He W (2007) Perspectives of γδ T cells in tumor immunology. Cancer Res 67:5PubMedCrossRef

27.

Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, Hildeman DA, Belkaid Y, Chougnet C (2008) Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 181:1835PubMed

28.

Lustgarten J, Dominguez AL, Thoman M (2004) Aged mice develop protective antitumor responses with appropriate costimulation. J Immunol 173:4510PubMed

29.

Mak TW, Ferrick DA (1998) The γδ T cell bridge: linking innate and acquired immunity. Nat Med 4:764PubMedCrossRef

30.

Massari I, Donnini A, Argentati K, Straino S, Mangoni A, Gaetano C, Viticchi C, Capogrossi MC, Provinciali M (2002) Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats. Exp Gerontol 37:823PubMedCrossRef

31.

Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P (2002) CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. PNAS 99:8832PubMedCrossRef

32.

Mumm JB, Oft M (2008) Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 27:5913PubMedCrossRef

33.

Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S (2006) CD4+CD25+Foxp3+ T cells and CD4+CD25−Foxp3* T cells in aged mice. J Immunol 176:6586PubMed

34.

Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS (1999) Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL 18, and IL-1 beta converting enzyme cDNA. Proc Natl Acad Sci 96:13351PubMedCrossRef

35.

Pawelec G, Solana R (1997) Immunosenescence. Trends Immunol 11:514

36.

Pertovaara M, Raitala A, Lehtimaki T, Karhunen PJ, Oja SS, Jylha M, Hervonen A, Hurme M (2006) Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality. Mech Ageing Dev 127:497PubMed

37.

Provinciali M, Fabris N, Pieri C (1990) Improvement of natural killer cell activity by in vitro active lipids (AL 721) administration in old mice. Mech Ageing Dev 52:245PubMedCrossRef

38.

Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624PubMedCrossRef

39.

Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A (2003) Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21:843PubMedCrossRef

40.

Provinciali M, Smorlesi A (2005) Immunoprevention and immunotherapy of cancer in aging. Cancer Immunol Immunother 54:93PubMedCrossRef

41.

Provinciali M, Donnini A, Smorlesi A, Gatti C (2008) Breast cancer and immunosenescence. In: Fulop T, Franceschi C, Hirokawa K, Pawelec G (eds) Immunosenescence handbook. Springer, Berlin (in press)

42.

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa S, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musini P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammari carcinomas in Her-2/neu transgenic mice. Cancer Res 64:2858PubMedCrossRef

43.

Re F, Poccia F, Donnini A, Bartozzi B, Bernardini G, Provinciali M (2005) Skewed representation of functionally distinct populations of Vγ9 Vδ2 T lymphocytes in aging. Exp Gerontol 40:59PubMedCrossRef

44.

Sansone P, Storci G, Tavolati S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988PubMedCrossRef

45.

Seth R-N (2006) Why cancer and inflammation? Yale J Biol Med 79:123

46.

Sharma S, Dominguez A, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol 41:78–84PubMedCrossRef

47.

Sharma S, Dominguez AL, Justgarten J (2006) High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol 177:8348PubMed

48.

Walker PR, Saas P, Dietrich P-Y (1997) Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J Immunol 158:4521PubMed

49.

Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904PubMedCrossRef

50.

Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea-a paradigm shift. Cancer Res 66:1883PubMedCrossRef

51.

Zamanakou M, Germenis AE, Karanikas V (2007) Tumor immune escape mediated by indole amine 2,3-dioxygenase. Immunol Lett 111:69PubMedCrossRef

52.

Zou W (2006) Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6:295PubMedCrossRef

Titel: Immunosenescence and cancer vaccines
verfasst von: Mauro Provinciali
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0665-z

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Immunosenescence and cancer vaccines

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

The importance of the age factor in cancer vaccination at older age

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53

The effect of aging on OX40 agonist-mediated cancer immunotherapy

Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie